Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)
Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1)
This is a phase IV, randomised, placebo-controlled, double-blind, parallel group study to
 determine the effect of Evolocumab treatment on carotid plaque morphology and composition in
 asymptomatic patients with >50% carotid artery stenosis.
In this study patients will be randomised in a 1:1 ratio to receive Evolocumab 140 mg every
 two weeks or matching placebo, to be administered for 12 months. After 12 months of
 treatment, patients will remain in follow-up for a further 12 months.

 High resolution magnetic resonance imaging (MRI) will be used to serially monitor the impact
 of Evolocumab on carotid plaque morphology and composition in patients with significant
 carotid stenosis who do not meet clinical criteria for carotid endarterectomy. This approach
 will reveal if clinically beneficial plaque regression occurs, without requiring the large
 patient cohorts or long follow-up needed for cardiovascular outcome trials.

 Results from this study will establish whether treatment with Evolocumab is likely to be
 beneficial to patients with asymptomatic carotid stenosis.
Inclusion Criteria:

 -  Age ≥18 years

 -  Sufficient English language ability to adequately understand the study

 -  Able to give informed consent

 -  Significant carotid artery plaque with 50-70% stenosis on ultrasound or MRI performed
 prior to screening

 -  Significant asymptomatic carotid artery plaque with >70% stenosis on ultrasound or MRI
 performed prior to screening, but carotid endarterectomy or carotid artery stenting
 has been deemed unsuitable by multidisciplinary team during routine clinical care

 -  Lipid-rich necrotic core (LRNC) on baseline MRI scan

 -  Adequate image quality for MRI analysis.

 -  LDL-C ≥2.6 mmol/L (100 mg/dL)

 -  On stable dose of maximally-tolerated lipid-lowering therapy in accordance with UK
 national clinical guidelines (NICE CG18120) for ≥2 months prior to screening.
 Acceptable non-statin lipid-lowering medications include ezetimibe or a fibrate.

 Exclusion Criteria:

 -  Any medical condition which, in the opinion of the investigators, would present an
 unacceptable risk to the participant if they were to take part in the trial, or
 prevent them from following the trial protocol

 -  Current or previous treatment with a PCSK9 inhibitor

 -  Eligible for PCSK9 inhibitor treatment under current NICE guidelines

 -  Contra-indication to or inability to use Evolocumab treatment, including:

 -  Sensitivity to Evolocumab or any associated excipients

 -  Unable to tolerate or perform self-administration of Evolocumab by auto-injector

 -  Lack of suitable refrigerated storage

 -  Contra-indication to or inability to tolerate MRI

 -  Estimated glomerular filtration rate (eGFR) ≤45 mL/min/1.73 m2 prior to MRI scan

 -  Pregnancy or breast-feeding

 -  Women of childbearing potential who are unwilling or unable to use a highly effective
 method of contraception